Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
5 hedge funds and large institutions have $50K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
58% less capital invested
Capital invested by funds: $119K → $50K (-$69K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$6K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$4.35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $21K | – | – | – |
|
|
ICM
2
Ionic Capital Management
New York
| $20K | -$4.35K | -18,176 | -12% |
|
|
3
BlackRock
New York
| $7K | +$11.2K | +46,688 | New |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | – | – | – |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| – | -$6K | -20,604 | Closed |
|
EYEGW Hedge Fund Activity: Q1 2017 in Review
5 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q1 2017, worth a combined $50K — down 58% from $119K a quarter earlier.
Fund positioning in EYEGW was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $11.2K. The largest seller was Sabby Management, exiting entirely with an estimated $6K sold.
- 5 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q1 2017, down from 6 in Q4 2016.
- Funds reported $50K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q1 2017, down 58% quarter-over-quarter.
- 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q1 2017 was BlackRock, an estimated $11.2K added.
- The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q1 2017 was Sabby Management, an estimated $6K sold.
Based on aggregated 13F filings for Q1 2017.